Minute Insight: Boston Scientific Walks Away From MI Tech Deal, Citing Regulatory Hurdles
Executive Summary
The Federal Trade Commission said it supports Boston Scientific’s decision to walk away from a planned $230m acquisition of Korea-based MI Tech. Boston Scientific said it could not obtain needed global regulatory approvals.
You may also be interested in...
Boston Scientific Adds More Non-Vascular Stents To MedSurg Business With MI Tech Acquisition
Boston Scientific will pay about $230m for 64% of Korea-based MI Tech, which developed the Hanarostent line of conformable, self-expanding metal stents for endoscopic and urologic applications.
News We’re Watching: Two Join Illumina Board, FDA Plans Health Equity Meeting, Pre-Eclampsia Test Cleared
This week, Illumina’s board added two independent members; the VA and the FDA agreed to collaborate on supply chain issues; and Think Surgical, Thermo Fisher Scientific and Blue Earth all landed FDA clearances.
Exec Chat: Abbott’s Burton Talks About Abbott’s Plans To Address Chronic Pain With SCS
Allen Burton, the medical director of Abbott’s neuromodulation business and a leader in pain medicine, talked to Medtech Insight about the FDA’s new labeling for Abbott’s spinal cord stimulation devices that includes non-surgical back pain.